Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205

NCT01247922 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT01247922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01247922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
May 23, 2011
Completion date
September 13, 2012
Enrollment
4 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma